By PPN News Staff
Canagliflozin (Invokana, Janssen) significantly reduced the combined risk for death from cardiovascular disease (CVD), myocardial infarction (MI) and nonfatal stroke versus placebo in patients with type 2 diabetes mellitus and CVD.
The results of the integrated analysis of the CANVAS (CANagliflozin CardioVascular Assessment Study) and CANVAS-R (a study of the renal effects) trials also showed that canagliflozin treatment was associated with a reduced risk for hospitalization for